Those studies showed that knockdown of SMYD3, in pancreatic cancer cell lines increased gemcitabine and AraC resistance during cytotoxicity assay, consistent with the results of the association analysis. This evidence concerns the gene SMYD3 and familial pancreatic carcinoma.